In conclusion, inhibition of sesn2 aggravated LPS-induced oxidative, apoptotic, and fibrotic reactions by inhibiting AMPK phosphorylation (Figure 6), suggesting that sesn2 is a novel potential therapeutic target for preventing the progression of cardiomyopathy-related molecular events. Here, PRKAB1 is linked to cardiomyopathy.